Biohaven Pharma (BHVN) Tops Q2 EPS by 31c

Biohaven Pharma (NYSE: BHVN) reported Q2 EPS of ($1.63), $0.31 better than the analyst estimate of ($1.94).

For earnings history and earnings-related data on Biohaven Pharma (BHVN) click here.

You May Also Be Interested In

• FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
• St. James's Place plc (STJ:LN) (STJPF) PT Raised to GBP20.50 at Deutsche Bank
• JPMorgan Downgrades Wipro Ltd. (WPRO:IN) (WIT) to Underweight